Source: European Medicines Agency
The Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for ocriplasmin (Jetrea®) for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter ?400 microns. VMT is an age-related progressive, sight-threatening condition that may lead to visual distortion, decreased visual acuity and central blindness. It is estimated to affect between 250,000 to 300,000 patients in Europe.
Ocriplasmin is a recombinant form of human plasmin, administered as a single intravitreal injection. It targets the protein fibres which cause the abnormal pulling between vitreous and macula that causes VMT. By dissolving these proteins, ocriplasmin releases…